EP2262834A4 - ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME - Google Patents

ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME

Info

Publication number
EP2262834A4
EP2262834A4 EP09715242A EP09715242A EP2262834A4 EP 2262834 A4 EP2262834 A4 EP 2262834A4 EP 09715242 A EP09715242 A EP 09715242A EP 09715242 A EP09715242 A EP 09715242A EP 2262834 A4 EP2262834 A4 EP 2262834A4
Authority
EP
European Patent Office
Prior art keywords
imitate
antibodies
making
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09715242A
Other languages
German (de)
French (fr)
Other versions
EP2262834A2 (en
Inventor
Jon A Weidanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECEPTOR LOGIC Inc
Original Assignee
RECEPTOR LOGIC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RECEPTOR LOGIC Inc filed Critical RECEPTOR LOGIC Inc
Publication of EP2262834A2 publication Critical patent/EP2262834A2/en
Publication of EP2262834A4 publication Critical patent/EP2262834A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP09715242A 2008-02-27 2009-02-27 ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME Withdrawn EP2262834A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6732808P 2008-02-27 2008-02-27
US19187108P 2008-09-12 2008-09-12
PCT/US2009/001290 WO2009108372A2 (en) 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof

Publications (2)

Publication Number Publication Date
EP2262834A2 EP2262834A2 (en) 2010-12-22
EP2262834A4 true EP2262834A4 (en) 2011-08-17

Family

ID=41016658

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09715242A Withdrawn EP2262834A4 (en) 2008-02-27 2009-02-27 ANTIBODIES THAT IMITATE L-CELL RECEPTORS AND METHODS OF MAKING AND USING SAME

Country Status (2)

Country Link
EP (1) EP2262834A4 (en)
WO (1) WO2009108372A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2694553B1 (en) * 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
KR102643923B1 (en) 2014-12-23 2024-03-05 이매틱스 바이오테크놀로지스 게엠베하 Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
SG10201913158PA (en) 2015-04-03 2020-02-27 Eureka Therapeutics Inc Constructs targeting afp peptide/mhc complexes and uses thereof
AU2021275049A1 (en) 2020-05-19 2022-12-22 Amgen Inc. MAGEB2 binding constructs

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
US20070092530A1 (en) * 2004-05-27 2007-04-26 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2007143104A2 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092530A1 (en) * 2004-05-27 2007-04-26 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2007143104A2 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEETHLING F A ET AL: "Assessing vaccine potency using TCRmimic antibodies", VACCINE, ELSEVIER LTD, GB, vol. 26, no. 25, 25 February 2008 (2008-02-25), pages 3092 - 3102, XP022710591, ISSN: 0264-410X, [retrieved on 20080225], DOI: 10.1016/J.VACCINE.2008.02.025 *

Also Published As

Publication number Publication date
WO2009108372A3 (en) 2009-11-05
EP2262834A2 (en) 2010-12-22
WO2009108372A2 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
FR25C1034I1 (en) SELECTIVE ENHANCED PROTOFIBRILLA ANTIBODIES AND THEIR USE
EP2350655A4 (en) METHODS OF USING ANTIBODIES AND THEIR ANALOGUES
EP2507381A4 (en) PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
EP2307049A4 (en) NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF USE
EP2688403A4 (en) OPIOID RECEPTOR LIGANDS AND METHODS OF USE AND PRODUCTION THEREOF
EP2134852A4 (en) METHODS OF GENERATING ANTIBODIES
EP2847223A4 (en) ANTI-B7-H6 ANTIBODIES, FUSION PROTEINS, AND METHODS OF USE
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
EP2582729A4 (en) ANTI-AXL ANTIBODIES, AND METHODS OF USE.
EP2440228A4 (en) GLUCOSE REGULATION POLYPEPTIDES AND METHODS OF MAKING AND USING THEM
EP2553403A4 (en) REVERSIBLE PIEZOCHROMIC SYSTEM, METHODS OF MAKING AND USING REVERSIBLE PIEZOCHROMIC SYSTEM
EP2440241A4 (en) GROWTH HORMONE POLYPEPTIDES AND METHODS OF MAKING AND USING THEM
EP2252631A4 (en) SPECIFIC ANTIBODIES OF THE BCR COMPLEX AND METHODS OF USING SAME
EP2091975A4 (en) ANTI-EGFR FAMILY ANTIBODIES, BISPECIFIC ANTI-EGFR FAMILY ANTIBODIES AND METHODS OF USE THEREOF
EP2427479A4 (en) ANTIBODIES AND METHODS OF USE THEREOF
EP2552959A4 (en) ANTI-MUC16 ANTIBODIES AND METHODS OF USE
EP2076614A4 (en) SYNTHETIC ANTIBODIES
EP2212432A4 (en) FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USE
EP2539471A4 (en) MODIFIED PROTEINS AND METHODS OF MAKING AND USING THE SAME
EP2068887A4 (en) SP35 ANTIBODIES AND USES THEREOF
EP2373691A4 (en) ANTI-FXI ANTIBODIES AND METHODS OF USE
EP2542576A4 (en) METHODS FOR SCREENING ANTIBODIES
EP2874997A4 (en) NOVEL SIGMA RECEPTOR LIGANDS AND METHODS OF MODULATION OF CELL PROTEIN HOMETOSASE USING THE SAME
EP2819695A4 (en) EPITHELIAL CELL ADHESION ANTI-MOLECULE ANTIBODIES (EPCAM) AND METHODS OF USING SAME
EP2172483A4 (en) ANTI-MUC17 ANTIBODIES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100927

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20110718

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/39 20060101ALI20110712BHEP

Ipc: C07K 16/30 20060101ALI20110712BHEP

Ipc: C07K 16/28 20060101AFI20110712BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120215